Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Total Revenue of $0.00 for fiscal year 2022.
Corbus Pharmaceuticals Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $0.00 -100.0% |
$881.7K -77.6% |
$3.94M -89.1% |
| Revenue (ASC 606) | — | — | — | $0.00 -100.0% |
$881.7K -77.6% |
$3.94M -89.1% |
| Net Income | -$78.54M -95.3% |
-$40.21M +9.9% |
-$44.60M -5.3% |
-$42.35M +7.2% |
-$45.64M +59.0% |
-$111.27M -55.7% |
| Diluted EPS | -$5.90 -60.3% |
-$3.68 +64.3% |
-$10.31 -1.6% |
-$10.15 +9.0% |
-$11.15 | — |
| Total Assets | $168.19M +7.9% |
$155.88M +451.4% |
$28.27M -57.4% |
$66.31M -38.4% |
$107.73M +5.3% |
$102.29M +108.2% |
| Cash and Equivalents | $28.49M +65.7% |
$17.20M +25.3% |
$13.72M -19.3% |
$17.00M -32.0% |
$25.01M -70.7% |
$85.43M +169.1% |
| Long-Term Debt | — | — | $0.00 -100.0% |
$15.98M +2.2% |
$15.64M -13.3% |
$18.03M |
| Stockholders Equity | $147.50M +3.6% |
$142.43M +2162.7% |
-$6.91M -120.9% |
$32.99M -52.3% |
$69.11M +52.6% |
$45.27M +635.3% |
| R&D Expense | $70.09M +117.5% |
$32.22M +3.4% |
$31.17M +93.1% |
$16.14M -55.7% |
$36.45M -62.9% |
$98.27M +9.7% |
| Operating Income | -$85.31M -75.1% |
-$48.72M -8.1% |
-$45.08M -13.2% |
-$39.84M +28.9% |
-$55.99M +54.4% |
-$122.81M -59.3% |
| Shares Outstanding | 17.61M +44.6% |
12.18M +175.3% |
4.42M +6.1% |
4.17M +0.0% |
4.17M -95.8% |
98.85M +52.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2022 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$23.34M | -69.4% | -32.2% |
| Diluted EPS | September 30, 2025 | -$1.90 | -65.2% | -31.9% |
| Total Assets | September 30, 2025 | $109.51M | -33.3% | -12.4% |
| Cash and Equivalents | September 30, 2025 | $26.98M | +38.9% | +34.6% |
| Long-Term Debt | September 30, 2023 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $92.15M | -38.8% | -17.0% |
| R&D Expense | September 30, 2025 | $20.86M | +93.0% | +37.4% |
| Operating Income | September 30, 2025 | -$24.42M | -57.5% | -27.5% |
| Shares Outstanding | September 30, 2025 | 12.53M | +2.9% | +2.3% |
- Corbus Pharmaceuticals Holdings, Inc. reported Total Revenue of $0.00 for fiscal year 2022.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Net Income of -$78.54 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -95.3% in Net Income compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Diluted EPS of $5.90 per share (loss) for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -60.3% in Diluted EPS compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Total Assets of $168.19 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +7.9% in Total Assets compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Cash and Equivalents of $28.49 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +65.7% in Cash and Equivalents compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Long-Term Debt of $0.00 for fiscal year 2023.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Stockholders Equity of $147.50 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +3.6% in Stockholders Equity compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported R&D Expense of $70.09 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +117.5% in R&D Expense compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Operating Income of -$85.31 million for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -75.1% in Operating Income compared to the prior fiscal year.
- Corbus Pharmaceuticals Holdings, Inc. reported Shares Outstanding of 17.61 million shares for fiscal year 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +44.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: